Loading...
XNASLUMO
Market cap37mUSD
Dec 11, Last price  
4.34USD
Name

Lumos Pharma Inc

Chart & Performance

D1W1MN
XNAS:LUMO chart
P/E
—
P/S
18.30
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.54%
Rev. gr., 5y
11.20%
Revenues
2m
+34.67%
633,000934,0002,079,0001,872,0001,687,0001,093,000165,950,00036,143,0003,526,000390,0001,206,000936,000168,000230,0001,523,0002,051,000
Net income
-34m
L+9.57%
-9,162,000-9,442,000-16,213,000-18,087,000-23,321,000-31,180,000102,858,000-40,381,000-85,155,000-71,951,000-53,595,000-42,989,000-5,663,000-30,430,000-31,062,000-34,034,000
CFO
-31m
L+16.80%
-8,885,000-9,140,000-13,270,000-12,949,000-20,471,000-25,818,000109,068,000-24,087,000-65,947,000-48,281,000-37,939,000-30,207,000-22,997,000-29,648,000-26,623,000-31,095,000
Earnings
Mar 05, 2025

Profile

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
URL
https://lumos-pharma.com/
IPO date
Nov 11, 2011
Employees
32
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,051
34.67%
1,523
562.17%
230
36.90%
Cost of revenue
38,665
33,612
31,577
Unusual Expense (Income)
NOPBT
(36,614)
(32,089)
(31,347)
NOPBT Margin
Operating Taxes
(29)
(13)
(636)
Tax Rate
NOPAT
(36,585)
(32,076)
(30,711)
Net income
(34,034)
9.57%
(31,062)
2.08%
(30,430)
437.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
(585)
(821)
(192)
BB yield
2.26%
2.72%
0.33%
Debt
Debt current
564
233
352
Long-term debt
888
6,233
762
Deferred revenue
Other long-term liabilities
6,000
6,000
Net debt
(34,625)
(60,893)
(93,695)
Cash flow
Cash from operating activities
(31,095)
(26,623)
(29,648)
CAPEX
(21)
(30)
Cash from investing activities
10,742
(11,358)
25,970
Cash from financing activities
(576)
(821)
(192)
FCF
(36,905)
(31,634)
(7,224)
Balance
Cash
36,077
67,359
94,809
Long term investments
Excess cash
35,974
67,283
94,798
Stockholders' equity
(161,436)
(127,410)
(96,338)
Invested Capital
195,608
193,227
191,872
ROIC
ROCE
EV
Common stock shares outstanding
8,145
8,374
8,335
Price
3.18
-11.91%
3.61
-47.91%
6.93
-80.59%
Market cap
25,902
-14.32%
30,229
-47.66%
57,758
-76.14%
EV
(8,723)
(30,664)
(35,937)
EBITDA
(36,570)
(32,040)
(31,144)
EV/EBITDA
0.24
0.96
1.15
Interest
874
Interest/NOPBT